Curis Inc (CRIS): Total Assets
$19.97M
As of 2025-12-31
$18.97M
As of 2026-06-30
-43.2%
3-year compound annual growth
-37.2%
5-year compound annual growth
-14.4%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.97M | -51.6% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $41.27M | -46.6% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $77.28M | -29.0% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $108.85M | -32.9% | 2024-02-08, Balance as of period end |
| 2021-12-31 | $162.30M | -20.6% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $204.36M | +482.1% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $35.11M | -6.0% | 2021-03-16, Balance as of period end |
| 2018-12-31 | $37.37M | -49.4% | 2020-03-19, Balance as of period end |
| 2017-12-31 | $73.80M | +27.8% | 2019-03-26, Balance as of period end |
| 2016-12-31 | $57.75M | -39.2% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $94.97M | +51.7% | 2017-03-09, Balance as of period end |
| 2014-12-31 | $62.61M | -22.3% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $80.59M | +15.5% | 2015-02-24, Balance as of period end |
| 2012-12-31 | $69.77M | +44.8% | 2014-03-13, Balance as of period end |
| 2011-12-31 | $48.18M | -4.9% | 2013-03-13, Balance as of period end |
| 2010-12-31 | $50.65M | n/a | 2012-02-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Curis Inc (CRIS) | 2025-12-31 | $19.97M | -51.6% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $343.32M | +114.1% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $79.73M | +57.1% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $228.79M | -38.4% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $175.37M | -44.0% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $318.94M | -27.6% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $621.33M | -28.7% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $233.72M | +256.0% |
Compare CRIS, TSHA, ACOG, TCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗